Ken Griffin Relay Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,600 shares of RLAY stock, worth $61,152. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,600
Previous 1,500
940.0%
Holding current value
$61,152
Previous $10,000
540.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding RLAY
# of Institutions
207Shares Held
159MCall Options Held
100KPut Options Held
26.8K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$109 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15MShares$58.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$41.3 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY8.95MShares$35.1 Million3.17% of portfolio
-
Tang Capital Management LLC San Diego, CA8.07MShares$31.6 Million2.5% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $471M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...